GW's Epidiolex reduces seizures in expanded access study

GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) gained $12.57 (13%) to $108.75 on NASDAQ and 27.5p to 587p in London on Tuesday after data were published from an open-label study of Epidiolex cannabidiol in treatment-resistant epileptic patients in the company's expanded access program.

Among the 137 patients who completed 12 weeks of treatment, Epidiolex led to a 54% reduction in seizure frequency from baseline to week 12. The 213-patient study included 23 patients with Dravet syndrome who showed a 53% reduction in convulsive seizures, and 11 patients with Lennox-Gastaut syndrome (LGS) who showed a 55% decrease in atonic seizures. The most frequent adverse events were drowsiness, diarrhea, tiredness and decreased appetite. Twelve patients discontinued treatment. ...